ACLX Arcellx Inc

USD 53.62 0.00 0
Icon

Arcellx Inc (ACLX) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Neutral

Stock Target Advisor
Analysis
stockTargetAdvisor

Hold

Average User
Rating

USD 53.62

0.00 (0.00)%

USD 2.87B

0.44M

USD 80.58(+50.29%)

USD 26.50 (-50.58%)

Icon

ACLX

Arcellx Inc (USD)
COMMON STOCK | NSD
USD 53.62
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Neutral

Stock Target Advisor
Analysis
stockTargetAdvisor

Hold

Average User
Rating

USD 2.87B

USD 26.50 (-50.58%)

USD 53.62

Arcellx Inc (ACLX) Stock Forecast

Show ratings and price targets of :
USD 80.58
(+50.29%)

Based on the Arcellx Inc stock forecast from 8 analysts, the average analyst target price for Arcellx Inc is USD 80.58 over the next 12 months. Arcellx Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Arcellx Inc is Neutral, which is based on 4 positive signals and 4 negative signals. At the last closing, Arcellx Inc’s stock price was USD 53.62. Arcellx Inc’s stock price has changed by +7.80% over the past week, +3.81% over the past month and +29.49% over the last year.

No recent analyst target price found for Arcellx Inc
No recent average analyst rating found for Arcellx Inc

Company Overview Arcellx Inc

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical tri...Read More

https://arcellx.com

25 West Watkins Mill Road, Gaithersburg, MD, United States, 20878

130

December

USD

USA

Adjusted Closing Price for Arcellx Inc (ACLX)

Loading...

Unadjusted Closing Price for Arcellx Inc (ACLX)

Loading...

Share Trading Volume for Arcellx Inc Shares

Loading...

Compare Performance of Arcellx Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for ACLX

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Arcellx Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc 0.00 (0.00%) USD109.10B 27.47 20.00

ETFs Containing ACLX

Symbol Name ACLX's Weight Expense Ratio Price(Change) Market Cap

Frequently Asked Questions About Arcellx Inc (ACLX) Stock

Based on ratings from 8 analysts Arcellx Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 12 buy, sell and hold ratings.

Unfortunately we do not have enough data on ACLX's stock to indicate if its a good dividend stock.

Based on targets from 8 analysts, the average taret price for ACLX is USD 80.58 over the next 12 months. The maximum analyst target price is USD 87 while the minimum anlayst target price is USD 65.

Unfortunately we do not have enough data on ACLX's stock to indicate if its overvalued.

The last closing price of ACLX's stock was USD 53.62.

The most recent market capitalization for ACLX is USD 2.87B.

Based on targets from 8 analysts, the average taret price for ACLX is projected at USD 80.58 over the next 12 months. This means that ACLX's stock price may go up by +50.29% over the next 12 months.

We can't find any ETFs which contains Arcellx Inc's stock.

As per our most recent records Arcellx Inc has 130 Employees.

Arcellx Inc's registered address is 25 West Watkins Mill Road, Gaithersburg, MD, United States, 20878. You can get more information about it from Arcellx Inc's website at https://arcellx.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...